Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapsed/Refractory B-cell Lymphoma

In brief

1. Study Title: A Study on the Efficacy and Safety of Autocrine p40 CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cells (CD19/CD20-CAR.p40-T) in Relapsed/Refractory B-Cell Lymphoma 2. Study Objectives: * Primary Objective: To evaluate the safety of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma. * Secondary Objective: To evaluate the efficacy of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma. 3. Participant Intervention: * Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T cell infusion or CD19 CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.

Key facts

Study ID: NCT07097207
Run by: Shenzhen University General Hospital
People needed: 20
Starts: 2023-10-01
Expected to finish: 2026-09-30
Last updated by the study team: 2025-07-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Aged between 15 and 75 years old, regardless of gender;
Diagnosed with relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) diagnostic criteria;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
Expected survival time of ≥ 3 months;
Confirmation of CD20 expression in tumor cells by flow cytometry/immunohistochemistry;
Patients tolerant to CD19 CAR-T cell therapy or those with low CD19 expression;
No severe heart, lung, liver, or kidney diseases;
Capable of understanding and willing to sign the informed consent form for this trial;
No contraindications to peripheral blood apheresis for the subject;
Having clearly measurable and evaluable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard;
The subject must have received standard first- and second-line treatment regimens;
Not having received antibody-based drug treatment within 2 weeks before cell therapy.

You may not qualify if…

History of allergy to any component in the cell product;
The following conditions in the blood routine examination: White blood cell count (WBC) ≤ 1×10⁹/L, absolute neutrophil count (ANC) ≤ 0.5×10⁹/L, absolute lymphocyte count (ALC) ≤ 0.5×10⁹/L, platelet count (PLT) ≤ 25×10⁹/L;
The following conditions in laboratory tests: including but not limited to, total serum bilirubin ≥ 1.5 mg/dl; serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the upper limit of normal; serum creatinine ≥ 2.0 mg/dl;
Patients with heart failure classified as grade III or IV according to the New York Heart Association (NYHA) classification criteria; or left ventricular ejection fraction (LVEF) < 50% as detected by echocardiography;
Abnormal lung function with oxygen saturation < 92% under room air;
Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically severe heart diseases within 12 months before enrollment;
Grade 3 hypertension with poorly controlled blood pressure despite drug treatment;
History of craniocerebral trauma, disturbance of consciousness, epilepsy, severe cerebral ischemia or intracerebral hemorrhagic diseases;
Patients with autoimmune diseases, immunodeficiency, or other conditions requiring immunosuppressive agent treatment;
Presence of uncontrolled active infection;
Previous use of any CAR-T cell product or other genetically modified T cell therapies;
Vaccination with live vaccines within 4 weeks before enrollment;
Subjects positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Treponema pallidum particle agglutination assay (TPPA)/rapid plasma reagin (RPR), as well as HBV carriers;
History of alcohol abuse, drug abuse, or mental illness in the subject;
The subject participated in any other clinical study within 3 months before joining this clinical study;
Female subjects with any of the following conditions: a) Currently pregnant or breastfeeding; or b) Having a pregnancy plan during the trial period; or c) Being fertile but unable to take effective contraceptive measures;
Other circumstances that, in the opinion of the investigator, make the subject unsuitable for participation in this study.

Where it is running

Shenzhen University General Hospital — Shenzhen, Other (Non U.s.), China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.